Immatics (NASDAQ:IMTX) Shares Gap Up – Here’s Why

Posted by Geri Gentry on Oct 26th, 2026

Immatics N.V. (NASDAQ:IMTX – Get Free Report)’s share price gapped up prior to trading on Monday. The stock had previously closed at $7.31, but opened at $7.55. Immatics shares last traded at $7.20, with a volume of 30,596 shares changing hands.

Analysts Set New Price Targets

Several research analysts have recently issued reports on IMTX shares. Stifel Nicolaus initiated coverage on Immatics in a research note on Tuesday, October 13th. They set a “buy” rating and a $15.00 price target for the company. Jefferies Financial Group set a $17.00 price objective on shares of Immatics in a research note on Tuesday, August 25th. Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a report on Friday, September 18th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.67.

View Our Latest Research Report on IMTX

Immatics Stock Down 2.6%

The firm has a market capitalization of $973.23 million, a PE ratio of -3.83 and a beta of 1.36. The business’s fifty day moving average price is $8.44 and its 200 day moving average price is $9.57.

Immatics (NASDAQ:IMTX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.06). Immatics had a negative net margin of 495.71% and a negative return on equity of 47.41%. The firm had revenue of $10.44 million for the quarter, compared to analysts’ expectations of $12.42 million. As a group, sell-side analysts forecast that Immatics N.V. will post -1.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Immatics news, Director Perceptive Advisors Llc purchased 863,060 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were purchased at an average cost of $8.69 per share, with a total value of $7,499,991.40. Following the purchase, the director owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This represents a 8.31% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Doliver Advisors LP acquired a new position in shares of Immatics in the 3rd quarter valued at $263,000. Tidal Investments LLC raised its position in shares of Immatics by 0.7% in the 2nd quarter. Tidal Investments LLC now owns 171,499 shares of the company’s stock worth $1,737,000 after buying an additional 1,110 shares during the period. Engineers Gate Manager LP raised its position in shares of Immatics by 26.4% in the 2nd quarter. Engineers Gate Manager LP now owns 50,886 shares of the company’s stock worth $515,000 after buying an additional 10,638 shares during the period. Wellington Management Group LLP boosted its holdings in Immatics by 5.5% in the second quarter. Wellington Management Group LLP now owns 1,647,852 shares of the company’s stock valued at $16,693,000 after acquiring an additional 85,960 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Immatics by 87.5% in the first quarter. Bank of America Corp DE now owns 25,394 shares of the company’s stock valued at $250,000 after acquiring an additional 11,848 shares during the last quarter. Institutional investors and hedge funds own 64.41% of the company’s stock.

About Immatics

(Get Free Report)

Immatics N.V. is a biotechnology company developing T cell receptor (TCR)-based immunotherapies for cancer. The company’s approach is designed to recognize cancer-associated targets presented on the surface of tumor cells and activate the immune system against malignant tissue.

Its research and development programs include TCR-engineered T cell therapies, TCR bispecific molecules and other cell-based immunotherapies. Immatics has developed technology platforms intended to identify tumor targets and generate therapeutic TCRs, supporting programs for both solid tumors and blood cancers.